Rivoceranib
Metastatic Neoplasm
Wake Forest University Health SciencesSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Metastatic Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ny-Eso-1 Reactive Tcr Retroviral Vector Transduced Autologous Pbl Jonsson Comprehensive Cancer Center | Phase 1 | CC |
Ny-Eso-1 Peptide Vaccine Jonsson Comprehensive Cancer Center | Phase 1 | CC |
sar441000 Sanofi | Phase 1 | CC |
GEH200520 Merck Sharp & Dohme LLC | Phase 1 | CC |
mk-8294 Merck Sharp & Dohme LLC | Phase 1 | CC |
Fragmin M.D. Anderson Cancer Center | N/A | D |
Same molecule, other indications
Rivoceranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →